Sudeep Pharma Posts 9% Revenue Growth Despite 6% Profit Decline in Q2 FY26

Sudeep Pharma’s shares closed at ₹684, up 1.46%, after the company reported a 9% year‑on‑year increase in revenue for Q2 FY26. However, net profit fell by 6%, impacting operating margins despite strong topline growth. The company’s cost pressures led to a reduction in profit margins, even as the pharmaceutical company continues to see robust demand in its core product segments.